BCL2 Knockout AGS Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the AGS human gastric adenocarcinoma cell line. This product provides a heterogeneous mixture of edited cells harboring targeted disruption of the BCL2 gene, generated via CRISPR/Cas9-mediated gene disruption without clonal selection. The polyclonal format offers a more representative model of gene knockout effects across a cell population, facilitating studies that require averaging over multiple editing events. These cells enable interrogation of BCL2-dependent apoptosis and population-level responses.
The AGS cell line is a well-established epithelial model of gastric adenocarcinoma, carrying oncogenic KRAS G12D and PIK3CA E545K mutations that constitutively activate RAS/MAPK and PI3K/AKT signaling. These mutations drive proliferation and survival, in part through upregulation of anti-apoptotic proteins such as BCL2. The AGS background thus provides a clinically relevant context for studying apoptosis resistance in gastric cancer, particularly in the setting of hyperactive growth factor signaling.
BCL2 is a central anti-apoptotic regulator localized to the mitochondrial outer membrane, where it binds and neutralizes pro-apoptotic BAX and BAK. In the intrinsic apoptosis pathway, BCL2 prevents BAX/BAK oligomerization, cytochrome c release, and subsequent caspase-9 and caspase-3 activation. Its expression is transcriptionally regulated by STAT3, NF-??B, and the PI3K/AKT pathway, and post-transcriptionally by miR-15a/16. BCL2 also interacts with BH3-only proteins such as BIM, BAD, and BID, which compete for binding and can displace BAX/BAK. Disruption of BCL2 in these polyclonal knockout cells impairs this protective function, leading to increased susceptibility to BAX/BAK-mediated mitochondrial outer membrane permeabilization and cytochrome c release when subjected to intrinsic death signals.
In AGS cells, BCL2 knockout creates a unique platform for dissecting the interplay between oncogenic signaling and apoptosis. The co-occurrence of KRAS and PIK3CA mutations mimics common alterations in gastric adenocarcinoma, where BCL2 overexpression contributes to therapy resistance. Loss of BCL2 function is expected to lower the apoptotic threshold, enabling investigation of synergistic effects between targeted inhibitors (e.g., PI3K or MEK inhibitors) and pro-apoptotic stimuli. This model facilitates BH3 profiling and screening of BCL2 inhibitors or combinations to overcome gastric cancer resistance.
These polyclonal knockout cells are suitable for a wide range of apoptosis-focused assays. Western blotting and RT-qPCR can confirm BCL2 loss at the protein and mRNA level, respectively. Functional apoptosis assays??including Annexin V staining, caspase-3/7 activity measurements, and cytochrome c release assays??quantify the increased apoptotic sensitivity. BH3 profiling can map dependence on different anti-apoptotic proteins, while co-immunoprecipitation experiments allow examination of altered BCL2 interaction networks. Cell viability assays following treatment with standard chemotherapeutics or investigational agents further expand utility. For further technical details, please contact Ascent Research.
